Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2002 Jun;2(3):316-21.

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease.

Author information

  • 1Department of COPD Biology, UW 2532, GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406-0939, USA. amy.k.roshak@gsk.com

Abstract

Recent advances in our understanding of the role of cytokine networks in inflammatory processes have led to the development of novel biological agents for the treatment of chronic inflammatory diseases. At the present time, significant efforts are focused on characterizing the complex signal transduction cascades that are activated by these cytokines and, in turn, regulate their expression. The transcription factor NF-kappaB is a pivotal regulator of the inducible expression of key proinflammatory mediators, and activated NF-kappaB has been observed in several debilitating inflammatory disorders, including rheumatoid arthritis and osteoarthritis. In light of its central role in inflammation, the identification of inhibitors of NF-kappaB should provide novel therapeutics for the treatment of chronic joint disease.

PMID:
12020477
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk